Table 1 Baseline characteristics of 85 NSCLC patients

Gender

 Male

66

77.65

 Female

19

22.35

Ages

 < 60 years

40

47.06

 ≥60 years

45

52.94

Histology

 Adenocarcinoma

48

56.47

 Squamous cell carcinoma

37

43.53

AJCC TNM Stage

 Stage III

13

15.29

 Stage IV

72

84.71

Brain metastasis

 Yes

22

38.82

 No

63

61.18

Liver metastasis

 Yes

15

17.65

 No

70

82.35

Bone metastasis

 Yes

33

38.82

 No

52

61.18

Pleural effusion

 Yes

14

16.47

 No

71

83.53

Treatment line

 1 line

5

5.88

 2 lines

35

41.18

 ≥ 3 lines

45

52.94

PD-L1 expression

 Negative

44

51.76

 Low

28

32.94

 High

13

15.29

Actionable Driver Mutation

 Classical EGFR

14

16.47

 Unclassical EGFR

3

3.53

 ALK Fusion

2

2.35

 ROS1

2

2.35

 BRAF-V600E

2

2.35

 HER-2 20 insertion

2

2.35

 KRAS

14

16.47

  KRAS-G12C

5

5.88

  RAS-G12A

3

3.53

  KRAS-G12V

3

3.53

  KRAS-G12D

1

1.18

  KRAS-D119

1

1.18

  KRAS-L19F

1

1.18

History of smoke

 Yes

41

48.24

 No

44

51.76